文献速递类风湿关节炎

临床可疑关节痛阶段的功能受限与早期临床关节炎同样严重:一项纵向研究

Functional limitations in the phase of clinically suspect arthralgia are as serious as in early clinical arthritis; a longitudinal study.
PubMed 文献 · RMD Open · 2017-06-29

研究纳入241例病程<1年的临床可疑关节痛(CSA)患者,基线测定HAQ评分及单侧1.5T MRI评估亚临床炎症。中位随访103周,44例进展为临床关节炎。基线HAQ≥1.0与关节炎发展相关(HR=2.50,95%CI=1.03-6.10),且进展者从CSA至关节炎阶段HAQ评分无显著增加(0.88 vs 0.75,p=0.36),提示CSA阶段功能受限已与早期临床阶段相当。

要点

  • CSA患者基线HAQ中位评分为0.50,已存在功能受限。
  • 基线HAQ≥1.0与临床关节炎发展相关(HR=2.50,95%CI=1.03-6.10)。
  • 进展者从CSA至关节炎阶段HAQ评分无显著增加(p=0.36)。

核心结论

  • 临床可疑关节痛阶段的功能受限程度与早期临床关节炎阶段相当,从患者角度证实了该阶段的重要性。
  • 基线HAQ评分≥1.0与临床关节炎的发展相关。

研究设计与样本

  • 2012年4月至2015年3月纳入241例关节痛病程<1年且被风湿科医生认为有RA风险的患者。
  • 基线测定HAQ评分并完成单侧1.5T MRI(掌指关节、腕关节及跖趾关节),随访关节炎发展并重复HAQ评分。

主要发现

  • CSA初诊时HAQ评分中位数为0.50。
  • 较高的MRI炎症评分与较高的HAQ评分相关(β=0.017,95%CI=0.004-0.030)。
  • 中位随访103周期间,44例进展为临床关节炎。
  • 基线HAQ≥1.0与关节炎发展相关(HR=2.50,95%CI=1.03-6.10)。
  • 进展者从CSA初诊至关节炎发展,HAQ评分中位数无显著增加(0.88 vs 0.75,p=0.36)。

关键数值与推荐

  • MRI亚临床炎症评分为滑膜炎、腱鞘炎及骨髓水肿评分之和(范围0-189)。
  • 基线HAQ评分≥1.0与临床关节炎发展相关(HR=2.50,95%CI=1.03-6.10)。

临床怎么用

  • 对CSA患者应关注功能受限,基线HAQ≥1.0提示关节炎进展风险较高。
  • CSA阶段的功能受限已与早期关节炎相当,支持早期识别和干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A phase of arthralgia may precede the emergence of rheumatoid arthritis (RA). Although several studies have focused on biomarkers, the relevance of this phase for patients is less studied. It is unknown if patients already have functional limitations and if this is correlated to the extent of subclinical inflammation. Therefore, we assessed functional disability in patients with clinically suspect arthralgia (CSA), its association with MRI-detected subclinical inflammation and its course during progression to clinical arthritis. METHODS: From April 2012 to March 2015, 241 patients had arthralgia for <1 year and were, based on clinical presentation, considered at risk for RA by their rheumatologists. At baseline, Health Assessment Questionnaire (HAQ) scores were determined and unilateral 1.5 T MRI of metacarpophalangeal, wrist and metatarsophalangeal joints were made. Presence of MRI-detected subclinical inflammation was assessed by summing synovitis, tenosynovitis and bone marrow oedema scores (range 0-189). Patients were followed on arthritis development and HAQ scores were repeated when clinical arthritis had developed. RESULTS: The median HAQ score at presentation with CSA was 0.50. Higher MRI-inflammation scores were associated with higher HAQ scores (β=0.017, 95% CI=0.004 to 0.030). During median 103 weeks follow-up, 44 patients progressed to clinical arthritis. HAQ scores ≥1.0 were associated with arthritis development (HR=2.50, 95% CI=1.03 to 6.10). Within converters, median HAQ scores did not increase from presentation with CSA to arthritis development (0.88 and 0.75, p=0.36). CONCLUSIONS: HAQ scores ≥1.0 at presentation were associated with the development of clinical arthritis. Functional limitations in the prearthritis phase of CSA were as serious as in the early clinical phase, demonstrating the relevance of CSA from patients' perspectives.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Ten Brinck RM, van Steenbergen HW, Mangnus L, et al. Functional limitations in the phase of clinically suspect arthralgia are as serious as in early clinical arthritis; a longitudinal study. RMD Open. 2017. PMID: 28879045. doi:10.1136/rmdopen-2016-000419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。